- The approval is based on two P-III studies assessing the safety and efficacy of Supemtek (quadrivalent recombinant influenza vaccine) in 10,000 patients with influenza aged > 18yrs. Supemtek is 1st and only recombinant influenza vaccine approved in the EU
- The P-III efficacy study demonstrated improved protection against influenza compared to standard-dose influenza vaccine and reduced the risk of influenza by an additional 30% in adults aged ≥50yrs.
- Supemtek contains three times more antigen than both egg-based and cell-based standard-dose vaccines. Supemtek is also approved in the US under the tradename Flublok Quadrivalent
Click here to read full press release/ article | Ref: Sanofi | Image: Sanofi